#MSParis2017 – MS Therapy Aubagio Does Not Appear to Cause Birth Defects, Study Reports
News
Sanofi Genzyme’s multiple sclerosis therapy Aubagio (teriflunomide) does not appear to cause birth defects in humans as it does in laboratory animals, researchers concluded after studying more than ... Read more